Ysios Capital, a prominent Spanish life sciences venture capital firm, has announced the launch of InceptionBio, a new fund with a $115 million target. This initiative is dedicated to creating and developing early-stage biotechnology companies, with a primary focus on Spain's scientific ecosystem. The fund has secured its first closing with backing from the Spanish government's CDTI through its Innvierte programme.
A Strategic Focus on Early-Stage Innovation
InceptionBio will concentrate on identifying high-quality science from universities and research centers to build new enterprises. The fund's strategy prioritizes technology transfer and early-stage investments to accelerate scientific translation. This approach aims to transform promising discoveries into new therapies that can provide a meaningful impact for patients.
The new fund will be spearheaded by Managing Partner Joan Perelló and Partner Arturo Urrios, who bring extensive experience. This initiative complements Ysios Capital’s existing model by expanding its engagement to the earliest phases of company creation. It strengthens the firm's ability to support biomedical innovation from its inception through later-stage development.
Bolstering Spain's BioTech Ecosystem
The fund's strategy involves cultivating local scientific assets while also attracting international projects for development within Spain. This dual approach is designed to significantly strengthen the national biotech landscape. Ysios aims to help establish Spain as a leading European hub for biotechnology innovation and investment.
The partnership with CDTI-Innvierte underscores a powerful public-private collaboration in a strategic national sector. This backing is instrumental in accelerating technology transfer and fostering the growth of innovation-driven companies. Such support enhances the competitiveness of Spain’s research and development system on a global scale.
Ysios Capital's Established Track Record
Founded in 2008, Ysios Capital has established itself as a leading investor in the European life sciences sector. The firm manages over $461 million in assets across its funds and advises the Telescope Biotech Fund. This extensive experience provides a solid foundation for the new InceptionBio initiative and its goals.
The firm's history includes investments in more than 40 biotech companies, resulting in six NASDAQ exits and ten M&A transactions. Ysios was a key player in major Spanish deals, including the acquisitions of Tigenix and Sanifit. This proven track record highlights its ability to guide early-stage companies toward significant commercial success.
Future Outlook and Objectives
InceptionBio is already actively evaluating a pipeline of investment opportunities in advanced stages of review. The fund has set a clear objective to support the creation of at least three new biotech companies by 2026. This forward-looking target demonstrates a commitment to generating tangible results in the near term.
Leadership has articulated a clear vision for connecting science with capital to drive progress. Joan Perelló highlighted the opportunity to translate Spain's world-class science into globally impactful companies. Arturo Urrios added that the fund was created to bridge science, entrepreneurship, and investment to accelerate company formation.
The launch of InceptionBio represents a significant commitment to advancing Spain's biotechnology sector and fostering homegrown innovation. By focusing on the earliest stages of development, the fund is positioned to transform foundational science into viable therapies. With backing from an experienced firm like Ysios Capital and key public support, this initiative promises to accelerate medical breakthroughs.